Advancing Novel Biotherapeutics Since 1995®

Investor Relations

Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory indications. We utilize our proprietary drug discovery technology, phage display, to identify antibody, small protein and peptide compounds for clinical development. Dyax also leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Click here to learn more.

More »Stock Quote

DYAX (Common Stock)
Exchange NASDAQ (US Dollars)
Price $10.60
Change (%) 0.25 (2.42)%
Volume 723,000
Data as of Sep 17, 2014 4:00 PM ET
Delayed at least 20 minutes. Provided by eSignal.
Refresh Quote

More »Recent Releases

Date Title
Sep 15, 2014 Dyax Corp. Announces Issuance of Two Key U.S. Patents for DX-2930
Jul 29, 2014 Dyax Corp. Announces Second Quarter 2014 Financial Results
Jul 23, 2014 Dyax Corp. Announces Publication of Scientific Data for DX-2930 in Peer-Reviewed Journals
Jul 15, 2014 Dyax Corp. to Host Second Quarter 2014 Earnings Call and Webcast

More »Calendar of Events

Details on upcoming events are not yet available.

More » Event Archives

Jul 29, 2014 Dyax Corp. 2Q 2014 Earnings Call
Jun 17, 2014 2014 Wells Fargo Healthcare Conference
Jun 2, 2014 Jefferies Global Healthcare Conference
May 7, 2014 Deutsche Bank 39th Annual Health Care Conference

Featured Financial Reports

Filing Date Title Type Size
Aug 1, 2014 10-Q View HTML View PDF 541.1 KB Add to Briefcase
Dec 31, 2013 2013 Annual Report PDF  508.9 KB Add to Briefcase
Add to Briefcase = add file to Briefcase

You are now leaving Dyax.com.

The web site you are about to visit is . It is neither owned nor controlled by Dyax Corp. Dyax is not responsible for the content, products or services on this site.

Do you wish to continue?